Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)
Enrico Tiacci(University of Perugia), Robin Foà(Sapienza University of Rome), Simone Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Livio Trentin(University of Padua), Maura Nicolosi(Palmetto Hematology Oncology), Ombretta Annibali(Link Campus University), Francesca Ricci(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Luciana Morino(St. Eugenio Hospital), Valerio Leotta(Ospedale Garibaldi), Barbara Pocali(Azienda di Rilievo Nazionale ed Alta Specializzazione), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alessandro Gozzetti(University of Siena), Andrea Visentin(University of Padua), Caterina Stelitano(University of Reggio Calabria), Andrea Bernardelli(University of Verona), Monia Capponi(University of Perugia), Roberta Murru, Nilla Maschio(Ospedale Castelfranco Veneto), Jacopo Olivieri(Ospedale Santa Maria della Misericordia di Udine), Alessandro Mancini(University of Perugia), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Azzurra Anna Romeo(Ospedale Santa Maria Goretti), Silvia Trappolini(Ospedali Riuniti di Ancona), Michele Cimminiello(Ospedale San Carlo), Francesco Angotzi(University of Padua), Alessandro Pulsoni(Ospedale Santa Maria Goretti), Alessandro Sanna(Agence Régionale de Santé Nouvelle-Aquitaine), Flavio Falcinelli(University of Perugia), Carlo Visco(University of Verona), Brunangelo Falini(University of Perugia), Gianna Maria D’Elia(Sapienza University of Rome)
Cited by 1
Related Papers
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
|New England Journal of Medicine|2005|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k